statistics

The 2012 ACS Cancer Facts & Figures

Yesterday, The American Cancer Society (ACS) released their annual cancer statistics for the United States. Specific to prostate cancer, they indicated an increase in projected new prostate cancer diagnosis, but a decrease in prostate cancer deaths. In 2011, the ACS projected 240,890 new cases of prostate cancer; in 2012 they are projecting 241,740 new diagnoses. [...]

By Malecare|2021-02-17T11:03:31-05:00January 5th, 2012|Advanced Prostate Cancer, How We Live, Uncategorized|0 Comments

A Survival Advantage – Is It Worth It and What Does It Mean? When Economics Interface with Survival

In order to get FDA approval, drugs must first go through a clinical trial that demonstrates that they offer a better treatment result than the current standard of care. In some instances the better result can be a demonstration that the investigational drug provides an advantage which is only palliative (as Mitoxantrone does for advance [...]

By Malecare|2017-10-19T10:53:25-04:00November 30th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, General Information, How We Live, Provenge,